Horizon Therapeutics Public Limited Company

NasdaqGS:HZNP Stock Report

Market Cap: US$26.6b

Horizon Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Horizon Therapeutics has a total shareholder equity of $5.3B and total debt of $2.6B, which brings its debt-to-equity ratio to 48.2%. Its total assets and total liabilities are $9.3B and $4.0B respectively. Horizon Therapeutics's EBIT is $644.3M making its interest coverage ratio 9.4. It has cash and short-term investments of $2.5B.

Key information

48.2%

Debt to equity ratio

US$2.56b

Debt

Interest coverage ratio9.4x
CashUS$2.48b
EquityUS$5.31b
Total liabilitiesUS$3.99b
Total assetsUS$9.30b

Recent financial health updates

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25
These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Nov 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Sep 21

Horizon Therapeutics announces $500M buyback program

Sep 09

Horizon Therapeutics to expand footprint in Ireland

Aug 29

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Aug 22
Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Aug 19

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04
Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02
Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

Financial Position Analysis

Short Term Liabilities: HZNP's short term assets ($3.9B) exceed its short term liabilities ($917.7M).

Long Term Liabilities: HZNP's short term assets ($3.9B) exceed its long term liabilities ($3.1B).


Debt to Equity History and Analysis

Debt Level: HZNP's net debt to equity ratio (1.4%) is considered satisfactory.

Reducing Debt: HZNP's debt to equity ratio has reduced from 219.2% to 48.2% over the past 5 years.

Debt Coverage: HZNP's debt is well covered by operating cash flow (40.7%).

Interest Coverage: HZNP's interest payments on its debt are well covered by EBIT (9.4x coverage).


Balance Sheet


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.